Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856779 | 0.84 | ALDH1A1 (0.62) | CYP1A2ALDH1A1TSHRHPGDL3MBTL1 | |
| SCHEMBL31481622 | 0.84 | ALDH1A1 (0.62) | CYP1A2ALDH1A1TSHRHPGDL3MBTL1 | |
| SCHEMBL3625735 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TSHRL3MBTL1MEN1KMT2A | |
| SCHEMBL7821178 | 0.83 | CYP1A2 (0.40) | CYP1A2ALDH1A1TSHRHPGDL3MBTL1 | |
| SCHEMBL5095184 | 0.79 | KMT2A (0.47) | ALDH1A1TSHRHPGDMEN1KMT2A | |
| SCHEMBL1349897 | 0.78 | ALDH1A1 (0.55) | CYP1A2ALDH1A1TSHRHPGDMEN1 | |
| SCHEMBL752336 | 0.78 | ALDH1A1 (0.46) | CYP1A2ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL752337 | 0.78 | ALDH1A1 (0.46) | CYP1A2ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL29462217 | 0.78 | ALDH1A1 (0.46) | CYP1A2ALDH1A1TSHRMAPTKDM4E | |
| SCHEMBL74692 | 0.78 | CYP1A2 (0.62) | CYP1A2ALDH1A1TSHRHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-02-03 | — | — | US | disclosed |
| US-6835752-B2 | Can bind to Prostaglandin E2 receptors, especially, EP3 receptor and/or EP4 receptor and show antagonizing activity, and may be useful for prevention and/or treatment of disease, for example, pain, allergy, Alzheimer's disease, cancer | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| US-20040235825-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-11-25 | — | — | US | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| EP-1312601-A1 | CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| EP-0783318-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-10-20 | — | — | EP | disclosed |
| EP-0783318-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5585359-A | LACK OF THIOL MOIETY PREVENTS THIOL-DEPENDENT CHEMICAL REACTIONS AND REDUCES SYSTEMIC TOXICITY | MERCK & CO., INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996009836-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-04-04 | — | — | WO | disclosed |
| US-4886797-A | CENTRAL NERVOUS SYSTEM DISORDERS | A/S FERROSAN (DK) | 1989-12-12 | — | — | US | disclosed |
| US-4880799-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANTICONVULSANTS | A/S FERROSAN (DK) | 1989-11-14 | — | — | US | disclosed |
| US-4870073-A | CENTRAL NERVOUS SYSTEM DISORDERS, ANTHELMINTICS, PARASITICIDES, INSECTICIDES | A/S FERROSAN (DK) | 1989-09-26 | — | — | US | disclosed |
| EP-0220845-A1 | Heterocyclic compounds and their preparation and use | A/S FERROSAN (DK) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026908-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical aggents comprising the same as active ingredient | PTGER4, PTGER3, LTB4R | CYP1A2 174/4885ALDH1A1 399/4885TSHR 2539/4885 |
| US-20040235825-A1 | Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient | PTGER4, PTGER1, LTB4R | CYP1A2 133/4885ALDH1A1 224/4885TSHR 2511/4885 |
| US-20030216381-A1 | Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient | PTGER4, PTGER1, PTGER2 | CYP1A2 119/4885ALDH1A1 212/4885TSHR 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.